Literature DB >> 24492385

Rheumatoid arthritis: Are FcRL4+ B cells the next target for RA biologic therapy?

Nicholas J Bernard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24492385     DOI： 10.1038/nrrheum.2014.8

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis.

Authors:  L Yeo; H Lom; M Juarez; M Snow; C D Buckley; A Filer; K Raza; D Scheel-Toellner
Journal:  Ann Rheum Dis       Date:  2014-01-15       Impact factor: 19.103
  1 in total
  2 in total

1.  Characterization of human FCRL4-positive B cells.

Authors:  Michel Jourdan; Nicolas Robert; Maïlys Cren; Coraline Thibaut; Christophe Duperray; Alboukadel Kassambara; Michel Cogné; Karin Tarte; Bernard Klein; Jérôme Moreaux
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

2.  IL‑1β increases the expression of inflammatory factors in synovial fluid‑derived fibroblast‑like synoviocytes via activation of the NF‑κB‑mediated ERK‑STAT1 signaling pathway.

Authors:  Jie Yang; Junhu Wang; Xiaojun Liang; Hongmou Zhao; Jun Lu; Qiang Ma; Bingfei Jing; Feng Tian
Journal:  Mol Med Rep       Date:  2019-10-21       Impact factor: 2.952
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.